SCHEDULE: Orbis, Allan Gray Boost Genmab Stake to 5.3%

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have collectively increased their beneficial ownership in Genmab A/S to 5.3%, acquiring over 3.3 million shares.

Summary

• Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly reported beneficial ownership of 3,328,505 Genmab A/S securities.
• This holding represents 5.3% of the class of securities, which includes Ordinary Shares and American Depositary Shares (ADS).
• The total shares are comprised of 2,191,689 Ordinary Shares and 11,368,161 ADSs, with the ADSs representing an additional 1,136,816 Ordinary Shares.
• Orbis Investment Management Ltd holds 3,320,695 securities, while Allan Gray Australia Pty Ltd holds 7,810 securities.
• Both entities are classified as Non-U.S. Institutions (FI) equivalent to Investment Advisers (IA).
• The filing is an amendment (Amendment No. 3) to a Schedule 13G, indicating a change in ownership reporting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily reflecting a significant investment stake rather than new strategic developments or financial performance updates.

Positives

• Significant investment stake of 5.3% in Genmab A/S by Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd.
• Combined holding of over 3.3 million shares demonstrates strong investor confidence.

Negatives

• The filing does not provide any financial performance data or strategic updates for Genmab A/S.
• Details regarding the specific reasons for the increased stake are not disclosed.

Risks

• Potential for further market activity by these large shareholders could influence share price volatility.
• Lack of detailed disclosure on the investment strategy behind this stake leaves room for speculation.

Future Outlook

This filing is primarily a reporting of ownership levels and does not contain forward-looking statements or guidance from Genmab A/S.

Industry Context

StockSavvy.ai notes that significant stake building by institutional investors like Orbis and Allan Gray often signals a belief in the target company's long-term prospects, particularly in the biotechnology sector where Genmab operates. This filing suggests continued institutional interest in Genmab's pipeline and market position.

Stakeholder Impact

• Shareholders may view the increased stake as a positive signal of institutional confidence, potentially supporting share price.
• The increased concentration of ownership by these entities could influence future corporate governance decisions or strategic directions of Genmab A/S.

Next Steps

• Monitor future filings from Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd for any further changes in their stake.
• Observe Genmab A/S's operational and financial performance for insights into the underlying value driving investor interest.

Key Dates

Keywords

Genmab, Orbis Investment Management, Allan Gray Australia, Schedule 13G, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Investment Adviser